EMA warns: Ozempic could increase eye risk to diabetics!

EMA warns: Ozempic could increase eye risk to diabetics!

The European Medicines Agency (EMA) has found a possible connection between the drug Semaglutid, which is contained in preparations such as Ozempic, Wegovy and Rybelsus and a rare eye disease. According to a report by kosmo the risk of a non-arteriore ischemic optics neuropathy (naion) at Diabetics who take these medication. Naion can cause serious visual disturbances and arises from a reduced blood flow to the optic nerve.

The EMA classifies Naion as a "very rare side effect" that affects a maximum of one of 10,000 people treated. Nevertheless, the increasing use of Semaglutid, especially in the form of Ozempic and Wegovy for the treatment of type 2 diabetes and for weight loss, triggered concerns.

review of Danish studies

In addition, the EMA will check two Danish studies that examine a possible connection between Semaglutid and Naion. These studies are based on patient data from Danish and Norwegian registers and were carried out by the University of South Denmark in cooperation with the Norwegian Institute for Public Health. Researchers report that the new register -based studies show that the likelihood of developing Naion is more than doubled, such as Ophthalmology Times reported.

The Danish drug authority has asked EMA to evaluate these studies. Although earlier research could not prove an adequate connection, the new findings of these investigations could provide revealing information.

eye controls recommended

Experts recommend that existing eye damage should be examined before the start of therapy with Semaglutid. In a report by Diabinfo It is pointed out that regular eye examinations are important during treatment, Since Semaglutid can even worsen existing diabetic retinopathies.

In addition to these recommendations, a meta -analysis of seven studies with a total of 56,000 participants shows that there is an increased risk of diabetic retinopathies while taking Semaglutid. Experts advise you to weigh the risk of eye diseases against the positive effect of Semaglutid on cardiovascular events.

The EMA has not recommended that to end treatment with Semaglutide for the time being, but calls on both doctors and patients. The European Commission is responsible for the final decision to update the product information.